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Purpose: To assess pharmacodynamic and safety proﬁles of ONO-
9054 following single and multiple day dosing in subjects with
ocular hypertension or open-angle glaucoma.
Materials and Methods: This was a phase I, single-center,
randomized, double-masked, placebo-controlled dose-escalation
study. Nine subjects were randomized to each of ONO-9054 3, 10,
20, 30mg/mL and 12 to placebo. Subjects received a single drop to
each eye at 07:00±30 minutes (single dose). Following a 4-day no-
treatment period, subjects were dosed once daily for 14 consecutive
days (multiple day dosing). Intraocular pressure (IOP) was meas-
ured regularly and compared with baseline measurements. Ocular
examinations assessed safety and tolerability.
Results: Mean IOP decreased dose dependently. Following single
dosing, IOP decreased from 22.9±4.0 to 15.9±2.3mm Hg (ONO-
9054, 30mg/mL) at peak eﬀect 9 hours postdose; the reduction in
placebo-treated subjects was from 22.3±2.4 to 21.5±3.3mm Hg.
Following multiple day dosing, the greatest reduction in IOP occurred
1 hour postdose on day 18, from 23.3±0.6 to 15.1±2.4mm Hg
(ONO-9054, 10mg/mL); the smallest reduction at this time was from
23.9±0.8 to 18.6±2.0mm Hg (ONO-9054, 3mg/mL). Pressures
remained reduced on day 19, 25 hours after the last dose, when the
lowest measurement was 15.8±2.1mm Hg (ONO-9054, 10mg/mL).
Anterior uveitis and vitreous detachment were each reported in 2
subjects and considered moderate by the Investigator. Ocular hyper-
emia and tolerability symptoms were generally mild and transient.
Conclusions: ONO-9054 was well-tolerated and elicited dose-
dependent reductions in IOP, which were sustained for at least 24
hours following 2 weeks of consecutive daily dosing.
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Primary open-angle glaucoma (OAG) is a chronic oculardisease that is progressive, usually bilateral, but often
asymmetric. Worldwide, approximately 44.7 million people
are aﬀected by this form of glaucoma and estimates put
prevalence in the United States in the range of 1.87 to 2.5
million people, aged 40 years or older.1 Clinical manifes-
tations of glaucoma include raised intraocular pressure
(IOP), optic disc or retinal nerve ﬁber layer structural
anomalies or defects, and visual ﬁeld abnormalities.2
Although glaucoma is not deﬁned by raised IOP, the
only treatment strategy approved and demonstrated to be
eﬀective for patients with glaucoma is to lower IOP in an
eﬀort to slow structural and visual degeneration.3 Several
classes of drugs have been indicated for topical therapy in
the form of eye drops. These act locally to alter the
homeostasis of the ﬂuid dynamics of the aqueous humor,
lowering IOP by a variety of mechanisms including facili-
tating aqueous outﬂow and decreasing aqueous produc-
tion.4 Where eye drops are considered insuﬃcient, surgical
interventions including laser surgery, minimally invasive
glaucoma surgery, trabeculectomy, canaloplasty, and
drainage implants can improve outﬂow.5
Prostaglandin analogs (PGAs) are highly eﬀective
topical drugs that lower IOP by acting directly on the cil-
iary muscles, promoting relaxation and remodelling of the
extracellular matrix, thereby enhancing uveoscleral out-
ﬂow, and are often prescribed as ﬁrst-line treatment for
ocular hypertension (OHT) and primary OAG.6 Despite
the variety of treatments, however, there are still unmet
therapeutic needs: primary intervention often fails and so
over 40% of patients on PGA monotherapy eventually
require some form of adjunctive drug therapy to manage
IOP within a 5-year period.7
The PGAs latanoprost, bimatoprost, travoprost, and
taﬂuprost act primarily at the prostaglandin F (FP) recep-
tor, although lower activity for other prostaglandin recep-
tors has also been demonstrated.8 ONO-9054, also known
as sepetaprost, is a prodrug that is rapidly hydrolyzed by
esterases to its active metabolite ONO-AG-367, which
expresses high activity at both the prostaglandin E (EP3)
and FP receptors.9 ONO-9054 is known to enhance tra-
becular outﬂow as well as uveoscleral outﬂow in animals.10
ONO-9054 has been demonstrated to be safe and well-
tolerated in a single-dose escalation clinical study con-
ducted in healthy volunteers.11 The present phase I study
Received for publication July 13, 2015; accepted April 26, 2016.
From the *Indiana University School of Medicine, Indianapolis, IN;
wOno Pharma UK Ltd, London, UK; zOmar Consulting Group
LLC, Princeton Junction; yOno Pharma USA, Lawrenceville, NJ;
and 8Icahn School of Medicine at Mount Sinai, Mount Sinai
Hospital, New York, NY.
Dr Justin Cook and Dr Ellen Robertshaw of Niche Science and
Technology Ltd provided medical writing and submission support;
Ono Pharma UK Ltd paid for this service. ONO Pharma Japan
funded the study and participated in the design of the study, con-
ducting the study, data collection, data management, data analysis,
interpretation of the data and preparation, review, and approval of
the manuscript.
Disclosure: A.H., C.R.R. and J.B.S. were paid consultants to Ono
Pharma and C.L.W., T.O., A.W. and A.F. were employees of Ono
Pharma when the work was undertaken.
Reprints: Alon Harris, MS, PhD, FARVO, Indiana University School
of Medicine, 1160W. Michigan St., Indianapolis, IN 46202 (e-mail:
alharris@indiana.edu).
Copyrightr 2016 Wolters Kluwer Health, Inc. All rights reserved. This
is an open-access article distributed under the terms of the Creative
Commons Attribution-Non Commercial-No Derivatives License 4.0
(CCBY-NC-ND), where it is permissible to download and share the
work provided it is properly cited. The work cannot be changed in any
way or used commercially.
DOI: 10.1097/IJG.0000000000000449
ORIGINAL STUDY
e826 | www.glaucomajournal.com J Glaucoma  Volume 25, Number 10, October 2016
was completed to further assess safety and tolerability of
ONO-9054, as well as to characterize its pharmacokinetic
and pharmacodynamic proﬁles, following single and mul-
tiple day dosing in subjects with OHT or primary OAG.
MATERIALS AND METHODS
Subjects
The study population was comprised of men and
women aged 18 to 80 years, who had a diagnosis of bilateral
OHT or chronic primary OAG and were able to undergo
washout of all ocular hypotensive and other ocular drugs.
All subjects provided written, informed consent.
All subjects had IOPZ22mm Hg at 08:00 and
Z21mm Hg at 10:00 in at least 1 eye, with r35mm Hg at
all measurements in both eyes on the 2 days preceding
dosing (day 2 and 1) as measured by Goldmann
applanation tonometry. Additional eligibility requirements
for both eyes included central corneal thickness of 500 to
600 mm at screening; best-corrected visual acuity (BCVA) of
at least 20/100 as measured by Early Treatment Diabetic
Retinopathy Study chart and cup-to-disc ratio r0.8.
Exclusion criteria included history of severe ocular
trauma in either eye, intraocular or ocular laser surgery
within the previous 3 months; refractive surgery within the
previous 6 months; and signiﬁcant changes in visual ﬁelds
within 6 months of dosing as measured by 24-2 perimetry.
Subjects were excluded if any condition preventing reliable
screening or performance of ocular assessments was dis-
covered upon physical examination, as were those who had
received recent ocular, inhaled, intranasal, or systemic
administration of steroids, b-adrenergic blockers, adrener-
gic agonists, ocular allergy medications, carbonic anhy-
drase inhibitors, or cholinergic agonists.
Study Design
This was a phase I, single-center, randomized, double-
masked, placebo-controlled dose escalation study (clin-
trials.gov: NCT01670266), which took place from October
5, 2012 to May 9, 2013, inclusive, at a clinical research
organization (West Coast Clinical Trials, Costa Mesa, CA).
The study protocol was approved by the Aspire Institu-
tional Review Board (Santee, CA). The study was con-
ducted in accordance with the ethical principles of Good
Clinical Practice and the Declaration of Helsinki and
complied with the Health Insurance Portability and
Accountability Act.
Subjects were screened for eligibility in the 45 days
preceding the study. Washout of topical or systemic IOP-
lowering medications was performed according to the fol-
lowing schedules: 28 days for PGAs, b-adrenergic blockers,
or local or systemic steroids and glucocorticoids; 14 days
for adrenergic agonists or drugs for the treatment of ocular
allergy; 5 days for cholinergic agonists or carbonic anhy-
drase inhibitors.
The study consisted of 3 parts: a single-dose period of
4 days (subjects received 1 dose of drug in the morning on
day 1 and no treatment on days 2 to 4); a multiple day
dosing period during which subjects received treatment
once daily in the morning for 14 days (days 5 to 19); and a
follow-up visit on day 25 (±3d).
A randomized treatment assignment schedule was
prepared by an independent Statistician and Programmer
at the Contract Research Organisation, which assigned
each subject to either active or placebo treatment in a 3:1
ratio (active:placebo). Nine subjects were randomized to
each of ONO-9054 3, 10, 20, or 30mg/mL; and 12 subjects
were randomized to placebo as control. One drop
(approximately 30 mL) was administered to both eyes of
each subject once daily at 07:00±30 minutes.
Pharmacodynamics
All IOP measurements were obtained by 2 examiners
using calibrated Goldmann applanation tonometry: the
masked operator viewed the mires and applanated by
rotating the tonometer dial while the second operator
recorded the result. Baseline IOP was measured on day 1
at 5 timepoints (08:00, 10:00, 12:00, 16:00, and 19:00).
During the single-dose period, IOP was assessed 1, 3, 5, 9,
12, 25, 27, 29, and 33 hours postdose. During the multiple
day dosing period, IOP was assessed on days 5, 6, 11, 18,
and 19 at 1, 3, 5, and 9 hours postdose. All IOP measure-
ments were compared with corresponding measurements
taken at baseline on day 1. On day 18, following the
conclusion of multiple day dosing, IOP was assessed 1, 3, 5,
9, 12, 25, 27, 39, and 33 hours postdose. In all IOP analyses,
only data from the eligible eye was used (eligibility was
deﬁned as IOPZ22mm Hg at 08:00 and Z21mm Hg at
10:00, but r35mm Hg at all timepoints on days 2 and
1). If both eyes were eligible, the eye with the higher IOP
at 08:00 on day 1 was selected, and if both had the same
IOP the right eye was selected.
Pharmacokinetics
Peripheral blood samples were taken on days 1 and 18
predose and 5, 10, 20, 30, and 45 minutes and 1, 1.5, 2, 4,
and 6 hours postdose. On day 11, a sample was taken
10 minutes postdose. Plasma concentrations of ONO-9054
and the active metabolite ONO-AG-367 were determined
using validated liquid chromatography/tandem mass spec-
trometry (LC/MS/MS) methods at Quintiles BioSciences
Inc. (Ithaca, NY).
Plasma concentration versus time data were analyzed
using Phoenix WinNonlin version 6.2.1, utilizing a standard
noncompartmental model. When concentrations allowed,
the following plasma pharmacokinetic parameters were
derived for ONO-9054 and ONO-AG-367: maximum
observed concentration (Cmax), area under the concen-
tration-time curve from time 0 to the last sampling point
(AUClast; day 1 and day 18) and time 0 to inﬁnity (AUCinf;
day 1 only), time to Cmax (Tmax), elimination half-life (T½),
apparent clearance (CL/F; day 1 only), and corrected Cmax
and AUClast for dose per kg of body weight (BW) [Cmax/
(dose/BW) and AUClast/(dose/BW)].
Safety
Adverse events were recorded from day 1 to follow-up
and coded using the Medical Dictionary for Drug Regu-
latory Aﬀairs (MedDRA) dictionary (version 15.1). Clinical
laboratory evaluations, vital signs, and 12-lead electro-
cardiographs were also assessed.
Ocular hyperemia was evaluated grossly by compar-
ison of each eye to standardized photographs of con-
junctival hyperemia in subjects on glaucoma drug therapy
(use of Ora Calibra Redness Scale #6.0b, Ora Inc., And-
over, MA, was made under license from Ora Inc.). The
hyperemia scale was: Z0 or 0.5=none; 1 or 1.5=mild; 2
or 2.5=moderate; 3=severe. Scores were gathered on
days 1, 1, 2, 4, 5, 6, 11, 18, 19, and at follow-up. When
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each eye had a diﬀerent score, the worst score recorded
from both eyes was used.
The tolerability of the eye drop was assessed by a
subjective rating of photophobia, itching, tearing, dryness,
and discharge. Subjects rated each parameter as 0 (absent),
1 (mild), 2 (moderate), 3 (severe with stinging or burning)
or 4 (severe with blurred or dim vision). The worst scores
from both eyes were recorded on days 1, 1, 2, 4, 5, 6, 11,
18, and 19 and follow-up.
Slit-lamp examination and pupillometry were con-
ducted as additional evaluators of safety and tolerability
predose and 1, 3, 5, 9, 12, and 25 hours postdose during the
single-dose period; and predose and 1, 3, 5, 9, hours post-
dose on days 5, 6, 11, and 18 during multiple day dosing.
Measurements were also taken 12 hours postdose on day 5,
and 12 and 25 hours after the ﬁnal dose. Other ocular safety
assessments included BCVA, central corneal thickness by
pachymetry, indirect ophthalmoscopy, fundus imaging,
impression cytology, and visual ﬁelds and were assessed
before the ﬁrst dose of study medication and postdose at
various timepoints throughout the study.
Statistical Considerations
No a priori statistical assumptions were made for
sample size, which was based on including suﬃcient sub-
jects to assess pharmacodynamics, pharmacokinetics, and
safety, while minimizing the risk to subjects in early drug
development, and was typical of similar phase I trials
investigating OAG.12,13 The Safety Set comprised all sub-
jects enrolled in the study who received at least 1 drop of
study medication of any strength (including placebo)
instilled in either eye. The Safety Set was used for analysis
of pharmacodynamic endpoints. The Pharmacokinetic
Analysis Population included all enrolled subjects who
received ONO-9054 and had at least 1 postdose PK blood
sample.
Two post hoc analyses were performed. An analysis
was conducted to evaluate the extent of IOP lowering in
subgroups of subjects that presented at baseline with
IOPZ24mm Hg as it has been identiﬁed that subjects with
a higher baseline IOP respond better to PGAs.14 A second
post hoc analysis evaluated mean diurnal IOP (08:00, 10:00,
12:00, 16:00, 19:00) in all subjects at baseline and day 18
and assessed for statistical signiﬁcance using Tukey’s (least
squares means) test. All P-values <0.05 were considered
statistically signiﬁcant.
RESULTS
Disposition and Demographics
A total of 113 subjects were screened and 48 subjects
were randomized; 36 received ONO-9054, 12 received pla-
cebo. One subject discontinued study medication on day 8
after receiving 4 doses of ONO-9054 30mg/mL because of
moderate bilateral anterior uveitis judged probably related.
The subject completed all safety assessments through day
18 and the bilateral uveitis was monitored until it resolved
without sequelae on day 32. All remaining subjects com-
pleted the study and received active drug and placebo as
planned. Subject demographics can be seen in Table 1.
Pharmacodynamics
Mean baseline IOP at 08:00 on day 1 ranged from
23.3±0.6mm Hg in the ONO-9054 10 mg/mL group to
25.2±2.5mm Hg in the 30 mg/mL group.
Single Dose
Following a single dose, ONO-9054 dose-dependently
reduced mean IOP. Peak eﬀect occurred 9 hours postdose on
day 1, when the greatest reduction was from a baseline value
of 22.9±4.0 to 15.9±2.3mm Hg (29.6%±11.6%) in
the ONO-9054 30mg/mL cohort. The smallest reduction in
mean IOP was from a baseline value of 22.6±1.3 to
19.3±3.0mm Hg (14.4%±12.1%) in the ONO-9054
10mg/mL cohort at this time and there was a reduction from
22.3±2.4 to 21.5±3.3mm Hg (3.0%±14.8% mm Hg)
in placebo-treated subjects (Fig. 1). The lowest mean IOP
(15.0±3.0mm Hg) was observed in the 20mg/mL dose
group at 12 hours postdose. In all active treatment groups,
IOP increased slightly in the absence of continued dosing on
days 2 to 4, although IOP did not return to baseline values.
Multiple Day Dosing
Mean IOP was decreased throughout the multiple day
dosing phase (days 5 to 18) and reductions in all active
treatment groups were greater than placebo. All subjects who
received ONO-9054 experienced a reduction in IOP to
r18mm Hg after the multiple dosing phase, whereas all
placebo-treated subjects had IOP of Z18mm Hg at all
measurement times. The peak reduction in mean IOP on day
18 was from a baseline value of 22.1±0.8 to 13.8±1.8mm
Hg (37.6%±6.5%) at 12 hours postdose for the ONO-
9054 10mg/mL cohort; mean IOP in the placebo group
changed from a baseline value of 21.9±2.5 to 21.9±1.9mm
Hg must be an error in these #s there is no change in the mean
here? (+0.9%±12.1%) at this time (Figs. 2, 3).
Mean percent reductions in IOP from baseline at 08:00
(1 h postdose) on day 18 ranged from 35.4%±10.5%
(ONO-9054, 10 mg/mL) to 22.5%±6.7% (ONO-9054,
3 mg/mL). The IOP in the ONO-9054 10 mg/mL group at
08:00 after multiple day dosing was 15.1±2.4mm Hg. The
reduction from baseline in the placebo group was from
24.7±2.1 to 23.5±2.3mm Hg (5.0%±6.8%) at the
same time on this day (Figs. 2, 3). The numbers of subjects
who responded to multiple day dosing with IOP measure-
ments ofr16mm Hg at 1 hour postdose on day 18 in each
dose group were: 0/12 (0%) for placebo; 1/9 (11.1%) for
ONO-9054 3mg/mL; 7/9 (77.8%) for 10mg/mL; 4/9 (44.4%)
for 20 mg/mL; and 6/9 (66.7%) subjects in the 30mg/mL
cohort (Table 2).
Morning pressure remained at least 25% below baseline
on day 19, 25 hours after the last dose, in all active treatment
groups. The lowest mean IOP at this time was 15.8±2.1mm
Hg observed in the ONO-9054 10mg/mL cohort. The percent
reduction from baseline remained greater than 30% in this
dose group for all timepoints on day 19 through 33 hours
postdose. In the ONO-9054 10mg/mL dose group, >50% of
subjects had IOPs lower than 16mm Hg at all timepoints on
day 18 (Table 2). In the doses above 10mg/mL, >50% of
subjects had IOPs lower than 18mm Hg at all timepoints on
this day. Mean IOP had increased at follow-up (7±3d after
termination of dosing) in all cohorts; mean IOP measure-
ments were 24.1±3.3, 21.7±2.0, 23.7±3.5, 22.1±1.2,
and 24.3±3.1mm Hg for the ONO-9054 3, 10, 20, 30mg/
mL and placebo cohorts, respectively.
Post Hoc Analyses
The number of subjects with high IOP at baseline
(Z24mm Hg at 23 h predose on day 1) was 27: 8 for
placebo, 6 for ONO-9054 3 mg/mL, 2 for 10 mg/mL, 5 for
20 mg/mL, and 6 for 30mg/mL (Fig. 4). Mean baseline
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values for IOP ranged from 24.0±0.0mm Hg (ONO-9054,
10 mg/mL cohort) to 26.5±2.1mm Hg (ONO-9054, 30 mg/
mL cohort) at 08:00 on day 1. The greatest mean
reductions in IOP from baseline in this population occurred
1 hour postdose on day 6 for the 3 mg/mL [7.5±3.2mm
Hg (30.9%±14.8%)] and 20mg/mL [8.6±2.3mm Hg
(33.8%±8.8%)] cohorts; 1 hour postdose on day 11 for
the 30mg/mL cohort [10.1±2.2mm Hg (38.1%±
7.2%)]; and 9 hours postdose on day 11 in the 10mg/mL
cohort [11.0±2.8mm Hg (46.0%±8.5%)]. At the
end of the study, after multiple day dosing, the mean IOP of
subjects with a high IOP at baseline and who received active
treatment ranged from 15.5±2.1mm Hg (ONO-9054,
10 mg/mL) to 19.3±1.7mm Hg (ONO-9054, 3mg/mL) 1
hour postdose on day 18. The greatest percent reduction
from baseline in IOP was observed in the 30 mg/mL group
(36.8%±7.6%) at this time.
For all subjects, mean diurnal IOP (08:00, 10:00, 12:00,
16:00, and 19:00) at baseline ranged from 22.0±1.4mm Hg
(ONO-9054, 20mg/mL) to 23.9±2.6mm Hg (ONO-9054,
30mg/mL). Mean diurnal IOP values on day 18 were as
follows: 22.5±2.1mm Hg (2.7%±6.6%) for placebo,
TABLE 1. Subject Demographics
ONO-9054
Patient
Characteristics
Placebo
(n=12)
3 lg/mL
(n=9)
10lg/mL
(n=9)
20 lg/mL
(n=9)
30 lg/mL
(n=9)
Total
(n=48)
Mean age in
years±SD [range]
65.7±8.2 [55-79] 67.8±8.2 [55-80] 51.3±13.5 [30-72] 65.7±6.6 [58-77] 64.1±6.8 [50-74] 63.1±10.4 [30-80]
Sex [n (%)]
Male 3 (25.0) 2 (22.2) 4 (44.4) 3 (33.3) 3 (33.3) 15 (31.2)
Female 9 (75.0) 7 (77.8) 5 (55.6) 6 (66.7) 6 (66.7) 33 (68.8)
Race [n (%)]
White 10 (83.3) 7 (77.8) 7 (77.8) 7 (77.8) 7 (77.8) 38 (79.2)
Black or Afro-American 1 (8.3) 1 (11.1) 0 (0.0) 0 (0.0) 0 (0.0) 2 (4.2)
Asian 1 (8.3) 1 (11.1) 2 (22.2) 2 (22.2) 2 (22.2) 8 (16.7)
Prior use of IOP-lowering
medications [n (%)]
PGA 5 (41.7) 2 (22.2) 0 (0.0) 2 (22.2) 4 (44.4) 13 (27.1)
TCAI 3 (25.0) 4 (44.4) 0 (0.0) 5 (55.6) 0 (0.0) 12 (25.0)
b-blocker 0 (0.0) 1 (11.1) 1 (11.1) 4 (44.4) 0 (0.0) 6 (12.5)
a2 agonist 0 (0.0) 1 (11.1) 1 (11.1) 0 (0.0) 0 (0.0) 2 (4.2)
Fixed combinations 2 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (4.2)
IOP indicates intraocular pressure; PGA, prostaglandin analog; TCAI, topical carbonic anhydrase inhibitor.
FIGURE 1. Mean change from baseline in intraocular pressure (IOP) (mm Hg±SD) in subjects receiving ONO-9054 3 mg/mL (n), 10mg/
mL (J), 20mg/mL (B) or 30mg/mL (X) or placebo (+) during single dose (days 1 to 4) and 14 consecutive days dosing (days 5 to 18).
Subjects receiving ONO-9054 displayed reduced IOP following both treatment periods, whereas those receiving placebo did not.
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18.0±2.1mm Hg (19.7%±6.7%) for the ONO-9054
3mg/mL cohort, 15.0±2.0mm Hg (34.3%±8.2%) for
the ONO-9054 10mg/mL cohort, 16.5±2.1mm Hg
(24.5%±8.3%) for the ONO-9054 20mg/mL cohort, and
16.5±2.9mm Hg (30.4%±12.4%) for the ONO-9054
30mg/mL cohort. On day 18, diurnal IOPs for all subjects
displayed statistically signiﬁcant reductions compared with
placebo at all doses (ONO-9054, 3mg/mL: P=0.001; ONO-
9054, 10mg/mL: P<0.0001; ONO-9054, 20mg/mL:
P<0.0001; ONO-9054, 30mg/mL: P<0.0001). A statisti-
cally signiﬁcantly greater treatment eﬀect was observed in
both the ONO-9054 10mg/mL (P=0.007) and 30mg/mL
(P=0.023) cohorts compared with the ONO-9054 3mg/mL
cohort.
Pharmacokinetics
The plasma concentration of ONO-9054 was below
the limit of quantiﬁcation in all subjects who received
FIGURE 2. Mean reductions in intraocular pressure (IOP) (mm Hg±SD) from baseline at various timepoints on days 1 (A), 18 (B), or 19
(C) following treatment with ONO-9054 3, 10, 20, or 30 mg/mL or placebo. Reduced IOP was sustained for 12 hours following single
dose and was still markedly reduced 33 hours postdose (day 19, 16:00) following 14 consecutive days dosing.
FIGURE 3. Percent change in intraocular pressure (IOP) (%±SD) from baseline at various timepoints on days 1 (A) and 18 (B) following
treatment with ONO-9054 3, 10, 20, or 30mg/mL or placebo. Administration of ONO-9054 resulted in a greater reduction in IOP than
placebo after single dose and 14 consecutive days dosing.
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ONO-9054 and no pharmacokinetic parameters were
calculated.
For ONO-AG-367, median Tmax for all cohorts was
0.17 hours on days 1 and 18. Plasma mean T½ of ONO-
AG-367 ranged from 0.41 to 0.67 hours for all cohorts on
days 1 and 18. Increases in the plasma mean peak and total
exposures of ONO-AG-367 were observed with increased
concentrations on both days 1 and 18 (Fig. 5). Both Cmax
and AUClast on days 1 and 18 exhibited approximate dose
proportionality across the ONO-9054 dose range of 3 to
30 mg/mL and there was no accumulation following 14 days
of dosing across all concentrations.
Safety and Tolerability
There were no deaths, serious or severe adverse events,
and only 1 subject (in the ONO-9054, 30mg/mL group)
experienced an adverse event (bilateral anterior uveitis) that
led to study drug discontinuation and withdrawal from the
study.
Overall, 17 subjects reported 23 adverse events; 6 who
received placebo and 11 who received ONO-9054; all but 2
were considered mild. The proportion of subjects with one
or more ocular or systemic adverse events was: 6/12 (50%)
in the placebo group, which was greater than the 3mg/mL
treatment group (0/9, 0%), 10mg/mL treatment group (4/9,
44%), and 20mg/mL treatment group (2/9, 22.2%). In the
30 mg/mL cohort, the proportion was 5/9 (55.6%), a pro-
portion similar to placebo. The most frequently reported
systemic adverse event was headache (3/48), and the most
frequently reported ocular adverse events were anterior
uveitis (2/48) and vitreous detachment (2/48). There was no
TABLE 2. Categorical Analysis of Target IOPs on Day 18 at 1 Hour Postdose (08:00)
ONO-9054 [n/N (%)]
Timepoint (Hours
Postdose)
Target IOP
(mm Hg)
Placebo
(N=12)
3 lg/mL
(N=9)
10lg/mL
(N=9)
20lg/mL
(N=9)
30 lg/mL
(N=9)
1 r18 0/12 (0.0) 4/9 (44.4) 8/9 (88.9) 7/9 (77.8) 7/9 (77.8)
r16 0/12 (0.0) 1/9 (11.1) 7/9 (77.8) 4/9 (44.4) 6/9 (66.7)
3 r18 0/12 (0.0) 4/9 (44.4) 7/9 (77.8) 5/9 (55.6) 5/9 (55.6)
r16 0/12 (0.0) 2/9 (22.2) 5/9 (55.6) 4/9 (44.4) 2/9 (22.2)
5 r18 1/12 (8.3) 5/9 (55.6) 8/9 (88.9) 7/9 (77.8) 7/9 (77.8)
r16 0/12 (0.0) 2/9 (22.2) 8/9 (88.9) 5/9 (55.6) 6/9 (66.7)
9 r18 0/12 (0.0) 7/9 (77.8) 8/9 (88.9) 6/9 (66.7) 6/9 (66.7)
r16 0/12 (0.0) 2/9 (22.2) 6/9 (66.7) 4/9 (44.4) 5/9 (55.6)
12 r18 0/12 (0.0) 5/9 (55.6) 9/9 (100.0) 8/9 (88.9) 6/9 (66.7)
r16 0/12 (0.0) 2/9 (22.2) 8/9 (88.9) 6/9 (66.7) 5/9 (55.6)
IOP indicates intraocular pressure.
FIGURE 4. Mean reductions in intraocular pressure (IOP) (mm
Hg±SD) from baseline at all 5 timepoints on day 18 following 14
consecutive days treatment with ONO-9054 3, 10, 20, or 30 mg/
mL or placebo in patients with high baseline values (Z24mm
Hg). Reduced IOP was observed in all patients with high baseline
values who received ONO-9054.
FIGURE 5. Mean plasma ONO-AG-367 concentration time pro-
file presented on a linear (A) and semilogarithmic scale (B) of
patients receiving ONO-9054 3 mg/mL (J), 10mg/mL (K),
20mg/mL (B), or 30mg/mL (n). Metabolite displayed a dose-
proportionate decrease in plasma concentration over time.
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evidence of a dose-response trend for any local (ocular) or
systemic adverse event.
One event of moderate intensity presented as bilateral
anterior uveitis and was considered by the Investigator to
be probably related to the study medication. This occurred
on day 8; the subject was discontinued from study medi-
cation on the same day and completed all other safety
assessments through day 18. The subject was treated with a
tapering course of steroid eye drops and the bilateral uveitis
was monitored until it resolved without sequelae on day 32.
This subject was randomized to receive ONO-9054 30 mg/
mL. The second moderate adverse event was anterior
uveitis of the right eye which occurred in the ONO-9054
10 mg/mL cohort on day 11. The study drug was withdrawn
from the aﬀected eye, which was treated with a tapering
course of steroid eye drops and the event resolved without
sequelae. The subject completed the study.
Ocular hyperemia occurred acutely on days 1 or 2 after
dosing, and in most cases resolved within 24 hours. Of the
scores reported on days 1 or 2 postdose, the highest graded
score of 2 (moderate hyperemia) was observed in the ONO-
9054 20 and 30 mg/mL cohorts. Mean hyperemia scores
indicated that redness was mild or absent throughout the
study and all hyperemia scores had returned to baseline
ranges by follow-up (day 25).
The majority of parameters assessed for ocular toler-
ability were mild and transient. Severe dryness was reported
by 1 subject in the ONO-9054 10 mg/mL cohort predose on
day 5. The most common symptoms were itching and
dryness. There was no obvious relationship between dose of
ONO-9054 and ocular tolerability ﬁndings.
Corneal pachymetry revealed that the thickness of the
central cornea of 4 subjects was >600mm (placebo n=1;
ONO-9054, 3mg/mL, n=1) and 1 subject <500mm (pla-
cebo) on day 19, 25 hours postdose. All corneal thicknesses
were between 500 and 600mm at follow-up (day 25). Fifteen
subjects had slightly abnormal or abnormal impression
cytology scores at follow-up, which was an increase in
severity from baseline, although these scores were considered
consistent with the age of the study population. There were
no clinically signiﬁcant ﬁndings of BCVA, indirect oph-
thalmoscopy, fundus imaging, or visual ﬁeld assessments.
DISCUSSION
This was the ﬁrst clinical study that investigated the
pharmacodynamic potential of ONO-9054 in subjects with
early primary OAG or OHT. ONO-9054 is a prodrug that
is hydrolyzed to its active prostaglandin receptor agonist
form, ONO-AG-367, by esterases known to be present in
the cornea and other tissues. Preclinical data suggest that
the eﬃcacy of ONO-9054 in reducing IOP may be greater
than that of PGAs such as latanoprost,9,15 the most com-
monly prescribed single-agent topical therapy for glau-
coma. Single doses of ONO-9054 resulted in marked
reductions in IOP across all treatment groups that were
proportionate with dose concentration. The sustained
reduction of IOP in the absence of continued dosing in
subjects receiving ONO-9054 10 mg/mL and 30 mg/mL was
consistent with the requirements for once-daily admin-
istration. This could be attributable to the costimulation by
the metabolite ONO-AG-367 of both the EP3 and FP
receptors.9 Following multiple day dosing, all cohorts
receiving ONO-9054 demonstrated a reduction in mean
IOP, which was sustained even after cessation of drug
instillation for the 3 highest doses. It should be noted that
the baseline IOP at day 1 after washout of IOP reducing
drugs was used throughout as the baseline. Following the
single dose part of the study, the 3-day washout of ONO-
9054 was not suﬃcient for the IOP to return to predose
levels; however, the day 1 timepoint was considered an
appropriate baseline for both parts as it represents the IOP
before administration of ONO-9054.
This study was conducted in subjects with elevated
IOP; however, studies of other PGAs have used baseline
IOP entry criteria for phase II studies are usually higher
than those used in this phase I study. One reason for this
diﬀerence may be that subjects with more severe (mild-
moderate) glaucoma and higher untreated IOPs are rou-
tinely included in these studies. A meta-analysis of the
eﬃcacy of latanoprost revealed that a higher baseline IOP is
signiﬁcantly associated with a greater mean reduction in
IOP.14 To assess the IOP reducing capacity of ONO-9054 in
subjects with higher baselines, a subgroup analysis of those
with IOPZ24mm Hg, 23 hours predose, on day 1 was
conducted. Mean percent reductions in IOP from baseline
to day 18 were similar or greater in the higher baseline IOP
group (Fig. 4 compared with Fig. 2B), although as the
sample size in some of the dose groups was low, the rele-
vance of this information is unclear.
Pharmacological studies have shown that drugs applied
topically to the eye are only minimally absorbed into the eye
(2% to 10%) where they exert their local eﬀect.16,17 The
remainder of the topically applied drug can enter the sys-
temic circulation through the extensive network of con-
junctival vessels and through the nasolacrimal duct through
the highly vascularized nasal mucosa. Both of these routes
are rapid and bypass ﬁrst pass metabolism. In addition,
drug entering the nasolacrimal system may be swallowed
and absorbed via the stomach.16 In these ways a large
proportion of drug administered topically (over 80% in
some studies)18 may enter the systemic circulation rapidly,
with peak plasma concentrations reached between 5 and
30 minutes after instillation.17,19
Plasma concentrations of ONO-9054 were below the
assay’s limit of quantiﬁcation in all subjects who received
the drug. However, it was possible to characterize the
plasma proﬁle of ONO-AG-367. Not only was mean peak
concentration reached rapidly, it also declined rapidly with
no measureable concentrations after 6 hours on day 1 and 4
hours on day 18 with no accumulation following 14 days of
dosing across all doses. As minimal concentrations of active
metabolite were measured for very short periods of time
following dosing, systemic side eﬀects would not be
expected and were not observed.
Current prostaglandin therapies available in the
United States, United Kingdom, and Japan include bima-
toprost, latanoprost, travoprost, and taﬂuprost. This class
of drugs is recognized as having an excellent systemic safety
and tolerability proﬁle. Although there is extensive evidence
on the eﬃcacy of the individual prostaglandin drugs, data
determining the comparative eﬀectiveness of the 4 drugs are
limited, but suggest similar eﬃcacy eﬀects.7,20 PGAs are
associated with ocular adverse eﬀects, which are typically
observed after 3 to 6 months of dosing, including ocular
hyperemia, stimulation of eyelash growth, iris and peri-
ocular pigmentary changes, and prostaglandin associated
periorbitopathy.20–22 These side eﬀects were not reported in
this study, although this could possibly be due to the short
duration of dosing. With the exception of the highest dose
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group, the proportion of subjects with one or more ocular
or systemic adverse events was similar to those reported in
the placebo group and the majority were mild and 2 were
moderate in intensity. All concentrations of ONO-9054
were well tolerated over 2 weeks of dosing.
This study indicates that topical administration of
ONO-9054, a novel dual receptor agonist PGA, eﬀectively
lowers IOP in subjects with early primary OAG or OHT
following single and multiple day dosing, which was sus-
tained for at least 24 hours following 2 weeks of consecutive
once-daily morning dosing.
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